Last $95.21 USD
Change Today +1.79 / 1.91%
Volume 856.7K
As of 4:00 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Victor Kotelianski M.D., Ph.D.

Former Senior Vice President of Distinguished Alnylam Fellow and Member of Scientific Advisory Board, Alnylam Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 2 different industries.

66--

Background*

Dr. Victor E. Kotelianski, MD, PhD, has been Senior Vice President of Alnylam Pharmaceuticals Inc. since October 2008. Dr. Kotelianski provides continued support on evaluation and management of external initiatives, including delivery technologies, academic and corporate collaborations, and future spin-out opportunities. He served as Vice President of Research and Development of Alnylam Pharmaceuticals Inc., from April 2003 to August 2008. Dr. Kotelianski has been instrumental ...

Read Full Background

Corporate Headquarters*

300 Third Street
Cambridge, Massachusetts 02142

United States

Phone: 617-551-8200
Fax: 617-551-8101

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

There is no Education data available.

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

There is no Total Compensation data available.
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALNY:US $95.21 USD +1.79

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Ali Mortazavi Chief Executive and Director
Silence Therapeutics plc
70.0K GBP
Hans G. C. P. Schikan Chief Executive Officer and Member of Management Board
Prosensa Holding N.V.
--
Mark W. Schwartz Ph.D.Chief Executive Officer, President and Director
Galena Biopharma, Inc.
$490.0K
Mark J. Murray Ph.D.Chief Executive Officer, President and Director
Tekmira Pharmaceuticals Corporation
$377.5K
Kleanthis G. Xanthopoulos Ph.D.Chief Executive Officer, President, Principal Financial & Accounting Officer and Director
Regulus Therapeutics Inc.
$600.0K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALNYLAM PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.